Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹4,296 Cr
verified against source
Revenue YoY
20%
reported change
EBITDA
₹928 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Biocon delivered a strong Q2 FY26 with consolidated revenue of ₹4,296 crore (+20% YoY) and EBITDA of ₹928 crore (+29% YoY), driven by biosimilars (+25% YoY) and generics (+24% YoY). Biosimilar EBITDA margin expanded ~400bps to 25% on operating leverage. The balance sheet strengthened via structured debt repayment (Goldman Sachs, Kotak, Edelweiss), with annual interest savings of ~₹300 crore expected from FY27. Key launches included Ustekinumab, Aspart, Bevacizumab, and Aflibercept; Denosumab approval and CalRx insulin glargine partnership mark strategic wins. Syngene's CRDMO grew modestly at 2% but maintained FY26 guidance. Risks include competitive pricing pressure in biosimilars and potential formulary exclusions for insulin aspart.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects R&D investment for biosimilars to remain in the 7-9% range of segment revenue for FY26.
- Generics R&D spend is expected to be in the 8-10% range of segment revenue.
- Gross margins in generics are expected to improve in the second half of FY26, driven by new product launches.
- Syngene's performance in H1 is in line with expectations, and the company is maintaining its annual guidance for FY26.
Risks flagged
- Top formularies like Optum Rx and Express Scripts have excluded aspart as a class, potentially limiting TAM for Kirsty.
- Market share and ASPs are inversely proportional; increased competition could erode pricing and margins.
- Five players are already in the Denosumab market with five more in the pipeline, increasing competitive intensity.
- Fixed costs from three new facilities capitalized in FY25 continue to pressure generics margins.
Key quotes
- We are the first interchangeable biosimilar as far that the FDA has approved. It is indeed a very proud moment for us.
- We are not in a rush. We will do this in a responsible manner.
- We have a very balanced mix. There's no exposure in any one particular market.
Research modules